| Ra Capital Management, L.P. |
Non-Executive Director |
Tyra Biosciences, Inc. (TYRA)
|
2024-11-08 |
$16.25 |
0.0% |
1,220,681
|
$19,836,066 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Septerna, Inc. (SEPN)
|
2024-10-28 |
$18.00 |
0.0% |
4,170,000
|
$75,060,000 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Janux Therapeutics, Inc. (JANX)
|
2024-10-18 |
$44.75 |
0.0% |
1,200,000
|
$53,700,000 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Bicara Therapeutics Inc. (BCAX)
|
2024-09-16 |
$18.00 |
0.0% |
1,833,000
|
$32,994,000 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Artiva Biotherapeutics, Inc. (ARTV)
|
2024-07-22 |
$12.00 |
-0.7% |
8,333,333
|
$99,999,996 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Eliem Therapeutics, Inc. (ELYM)
|
2024-06-27 |
$3.84 |
97.1% |
13,008,546
|
$49,952,817 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Aerovate Therapeutics, Inc. (AVTE)
|
2024-06-17 |
$1.67 |
16.2% |
928,110
|
$1,549,944 |
| Ra Capital Management, L.P. |
Non-Executive |
Boundless Bio, Inc. (BOLD)
|
2024-04-02 |
$16.00 |
-80.0% |
312,500
|
$5,000,000 |
| Ra Capital Management, L.P. |
Non-Executive Director |
ARS Pharmaceuticals, Inc. (SPRY)
|
2024-03-27 |
$9.48 |
23.9% |
1,401,299
|
$13,289,410 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Nkarta, Inc. (NKTX)
|
2024-03-27 |
$10.00 |
-45.7% |
3,000,000
|
$30,000,000 |
| Ra Capital Management, L.P. |
Non-Executive Director |
LENZ Therapeutics, Inc. (LENZ)
|
2024-03-21 |
$105.21 |
-77.3% |
142,573
|
$15,000,075 |
| Ra Capital Management, L.P. |
Non-Executive Director |
89bio, Inc. (ETNB)
|
2024-03-04 |
$15.35 |
-44.3% |
1,350,000
|
$20,722,500 |
| Ra Capital Management, L.P. |
Non-Executive Director |
PepGen Inc. (PEPG)
|
2024-02-09 |
$10.64 |
-16.7% |
2,557,593
|
$27,212,790 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Solid Biosciences Inc. (SLDB)
|
2024-01-11 |
$5.53 |
53.9% |
904,160
|
$5,000,005 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Wave Life Sciences Ltd. (WVE)
|
2023-12-11 |
$5.00 |
4.6% |
1,000,000
|
$5,000,000 |
| Ra Capital Management, L.P. |
Non-Executive Director |
ARS Pharmaceuticals, Inc. (SPRY)
|
2023-09-21 |
$3.03 |
287.7% |
2,700,000
|
$8,183,526 |
| Ra Capital Management, L.P. |
Non-Executive Director |
ARS Pharmaceuticals, Inc. (SPRY)
|
2023-08-29 |
$6.20 |
89.5% |
3,750,000
|
$23,250,000 |
| Ra Capital Management, L.P. |
Non-Executive |
AN2 Therapeutics, Inc. (ANTX)
|
2023-08-18 |
$9.00 |
-88.6% |
1,777,778
|
$16,000,002 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Acumen Pharmaceuticals, Inc. (ABOS)
|
2023-07-21 |
$7.75 |
-70.7% |
5,161,290
|
$39,999,998 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Janux Therapeutics, Inc. (JANX)
|
2023-07-19 |
$12.46 |
250.8% |
495,008
|
$6,167,800 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Black Diamond Therapeutics, Inc. (BDTX)
|
2023-07-05 |
$5.00 |
11.6% |
935,850
|
$4,679,250 |
| Ra Capital Management, L.P. |
Non-Executive Director |
DICE Therapeutics, Inc. (DICE)
|
2023-03-30 |
$29.07 |
63.6% |
509,145
|
$14,798,693 |
| Ra Capital Management, L.P. |
Non-Executive Director |
DICE Therapeutics, Inc. (DICE)
|
2023-03-27 |
$26.99 |
76.2% |
498,556
|
$13,457,372 |
| Ra Capital Management, L.P. |
Non-Executive Director |
89bio, Inc. (ETNB)
|
2023-03-24 |
$16.25 |
-47.4% |
2,461,538
|
$39,999,992 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Mineralys Therapeutics, Inc. (MLYS)
|
2023-02-14 |
$16.00 |
-25.4% |
1,250,000
|
$20,000,000 |
| Ra Capital Management, L.P. |
Non-Executive |
Fulcrum Therapeutics, Inc. (FULC)
|
2023-01-20 |
$13.00 |
-33.6% |
1,923,076
|
$24,999,988 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Werewolf Therapeutics, Inc. (HOWL)
|
2023-01-06 |
$2.21 |
-7.7% |
1,853,000
|
$4,095,130 |
| Ra Capital Management, L.P. |
Non-Executive |
Fulcrum Therapeutics, Inc. (FULC)
|
2023-01-04 |
$7.28 |
18.6% |
180,703
|
$1,314,806 |
| Ra Capital Management, L.P. |
Non-Executive |
Fulcrum Therapeutics, Inc. (FULC)
|
2022-12-27 |
$5.99 |
44.0% |
4,089
|
$24,510 |
| Ra Capital Management, L.P. |
Non-Executive |
Fulcrum Therapeutics, Inc. (FULC)
|
2022-12-19 |
$5.90 |
46.3% |
98,787
|
$582,814 |
| Ra Capital Management, L.P. |
Non-Executive |
Fulcrum Therapeutics, Inc. (FULC)
|
2022-12-16 |
$5.44 |
58.6% |
2,403,049
|
$13,073,874 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Acrivon Therapeutics, Inc. (ACRV)
|
2022-11-17 |
$12.50 |
-35.5% |
3,389,500
|
$42,368,750 |
| Ra Capital Management, L.P. |
Non-Executive Director |
89bio, Inc. (ETNB)
|
2022-10-18 |
$7.65 |
11.8% |
1,172,741
|
$8,971,469 |
| Ra Capital Management, L.P. |
Non-Executive Director |
DICE Therapeutics, Inc. (DICE)
|
2022-10-17 |
$36.50 |
30.3% |
1,640,000
|
$59,860,000 |
| Ra Capital Management, L.P. |
Non-Executive |
AN2 Therapeutics, Inc. (ANTX)
|
2022-08-04 |
$7.51 |
-86.3% |
1,909
|
$14,330 |
| Ra Capital Management, L.P. |
Non-Executive |
AN2 Therapeutics, Inc. (ANTX)
|
2022-07-27 |
$7.78 |
-86.8% |
23,219
|
$180,675 |
| Ra Capital Management, L.P. |
Non-Executive Director |
89bio, Inc. (ETNB)
|
2022-07-01 |
$3.55 |
140.8% |
2,816,900
|
$9,999,995 |
| Ra Capital Management, L.P. |
Non-Executive |
AN2 Therapeutics, Inc. (ANTX)
|
2022-06-21 |
$7.99 |
-87.1% |
302
|
$2,413 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Wave Life Sciences Ltd. (WVE)
|
2022-06-16 |
$2.15 |
143.3% |
9,480,052
|
$20,382,112 |
| Ra Capital Management, L.P. |
Non-Executive |
AN2 Therapeutics, Inc. (ANTX)
|
2022-06-14 |
$7.95 |
-87.0% |
81,424
|
$647,402 |
| Ra Capital Management, L.P. |
Non-Executive Director |
PepGen Inc. (PEPG)
|
2022-05-10 |
$12.00 |
-26.2% |
3,229,200
|
$38,750,400 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Nkarta, Inc. (NKTX)
|
2022-04-26 |
$15.00 |
-63.8% |
2,200,000
|
$33,000,000 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Icosavax, Inc. (ICVX)
|
2022-03-29 |
$4.54 |
237.0% |
184,218
|
$836,883 |
| Ra Capital Management, L.P. |
Non-Executive |
AN2 Therapeutics, Inc. (ANTX)
|
2022-03-29 |
$15.00 |
-93.1% |
1,666,666
|
$24,999,990 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Cytek Biosciences, Inc. (CTKB)
|
2022-03-15 |
$12.31 |
-55.8% |
583,870
|
$7,188,926 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Cytek Biosciences, Inc. (CTKB)
|
2022-03-11 |
$12.86 |
-57.7% |
634,638
|
$8,158,671 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Cytek Biosciences, Inc. (CTKB)
|
2022-03-08 |
$12.74 |
-57.3% |
647,264
|
$8,248,255 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Cytek Biosciences, Inc. (CTKB)
|
2022-03-02 |
$12.95 |
-58.0% |
441,865
|
$5,721,951 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Cytek Biosciences, Inc. (CTKB)
|
2022-02-25 |
$13.23 |
-58.9% |
420,380
|
$5,559,664 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Cytek Biosciences, Inc. (CTKB)
|
2022-02-22 |
$14.06 |
-61.3% |
547,380
|
$7,695,707 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Cytek Biosciences, Inc. (CTKB)
|
2022-02-16 |
$14.89 |
-63.5% |
498,629
|
$7,426,825 |
| Ra Capital Management, L.P. |
Non-Executive Director |
DICE Therapeutics, Inc. (DICE)
|
2021-09-17 |
$17.00 |
179.7% |
1,400,000
|
$23,800,000 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Tyra Biosciences, Inc. (TYRA)
|
2021-09-17 |
$16.00 |
31.9% |
1,250,000
|
$20,000,000 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Eliem Therapeutics, Inc. (ELYM)
|
2021-08-12 |
$12.50 |
-39.4% |
3,200,000
|
$40,000,000 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Icosavax, Inc. (ICVX)
|
2021-08-02 |
$15.00 |
2.1% |
2,666,666
|
$39,999,990 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Cytek Biosciences, Inc. (CTKB)
|
2021-07-27 |
$17.00 |
-68.0% |
2,950,000
|
$50,150,000 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Acumen Pharmaceuticals, Inc. (ABOS)
|
2021-07-06 |
$16.00 |
-85.8% |
1,875,000
|
$30,000,000 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Aerovate Therapeutics, Inc. (AVTE)
|
2021-07-02 |
$14.00 |
-86.1% |
2,785,714
|
$38,999,996 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Werewolf Therapeutics, Inc. (HOWL)
|
2021-06-16 |
$12.77 |
-84.0% |
323,298
|
$4,129,398 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Janux Therapeutics, Inc. (JANX)
|
2021-06-15 |
$17.00 |
157.1% |
2,941,176
|
$49,999,992 |
| Ra Capital Management, L.P. |
Non-Executive Director |
89bio, Inc. (ETNB)
|
2021-06-02 |
$18.77 |
-54.4% |
22,138
|
$415,530 |
| Ra Capital Management, L.P. |
Non-Executive Director |
89bio, Inc. (ETNB)
|
2021-05-28 |
$18.60 |
-54.0% |
207,417
|
$3,857,063 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Werewolf Therapeutics, Inc. (HOWL)
|
2021-05-04 |
$16.00 |
-87.3% |
1,715,000
|
$27,440,000 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Solid Biosciences Inc. (SLDB)
|
2021-03-19 |
$1293.75 |
-99.3% |
9,807
|
$12,688,439 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Satsuma Pharmaceuticals, Inc. (STSA)
|
2021-02-26 |
$5.68 |
-80.6% |
1,232,394
|
$6,999,998 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Vor Biopharma Inc. (VOR)
|
2021-02-09 |
$18.00 |
-95.4% |
2,979,566
|
$53,632,188 |
| Ra Capital Management, L.P. |
Non-Executive |
PMV Pharmaceuticals, Inc. (PMVP)
|
2020-09-29 |
$18.00 |
-91.5% |
950,000
|
$17,100,000 |
| Ra Capital Management, L.P. |
Non-Executive |
Orchard Therapeutics plc (ORTX)
|
2020-09-24 |
$46.33 |
-64.0% |
76,902
|
$3,563,135 |
| Ra Capital Management, L.P. |
Non-Executive |
Dyne Therapeutics, Inc. (DYN)
|
2020-09-21 |
$19.00 |
77.1% |
660,000
|
$12,540,000 |
| Ra Capital Management, L.P. |
Non-Executive Director |
89bio, Inc. (ETNB)
|
2020-09-17 |
$28.00 |
-69.5% |
1,300,000
|
$36,400,000 |
| Ra Capital Management, L.P. |
Non-Executive |
iTeos Therapeutics, Inc. (ITOS)
|
2020-07-28 |
$19.00 |
-18.4% |
1,425,000
|
$27,075,000 |
| Ra Capital Management, L.P. |
Non-Executive |
Inozyme Pharma, Inc. (INZY)
|
2020-07-28 |
$16.00 |
-67.4% |
600,000
|
$9,600,000 |
| Ra Capital Management, L.P. |
Non-Executive |
Nkarta, Inc. (NKTX)
|
2020-07-14 |
$18.00 |
-69.8% |
3,333,333
|
$59,999,994 |
| Ra Capital Management, L.P. |
Non-Executive Director |
89bio, Inc. (ETNB)
|
2020-07-08 |
$27.50 |
-68.9% |
275,000
|
$7,562,500 |
| Ra Capital Management, L.P. |
Non-Executive |
Phathom Pharmaceuticals, Inc. (PHAT)
|
2020-04-01 |
$24.86 |
-27.8% |
117,600
|
$2,923,642 |
| Ra Capital Management, L.P. |
Non-Executive |
Phathom Pharmaceuticals, Inc. (PHAT)
|
2020-03-31 |
$24.58 |
-27.0% |
60,600
|
$1,489,264 |
| Ra Capital Management, L.P. |
Non-Executive Director |
Kala Pharmaceuticals, Inc. (KALA)
|
2020-03-13 |
$394.11 |
-98.5% |
126,869
|
$49,999,995 |
| Ra Capital Management, L.P. |
Non-Executive |
scPharmaceuticals Inc. (SCPH)
|
2020-02-14 |
$8.20 |
-36.7% |
271,993
|
$2,230,343 |
|
|
|
|
|
Return |
Profit / (loss) |
Cost |
|
|
|
Total |
|
-14.6% |
$-234,417,030 |
$1,607,556,238 |